This segment focuses on developing non-addictive pain management solutions, addressing both acute and chronic pain conditions. Key products include Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain, and Probudur (LBL100), a long-acting bupivacaine liposomal gel for postoperative pain management. Research and development efforts are directed towards optimizing drug delivery systems and formulations to enhance efficacy and duration of action. Clinical trials are conducted to validate the safety and effectiveness of these therapies, with a focus on reducing opioid dependence and improving patient outcomes. The market positioning emphasizes the non-addictive nature of the products, offering a competitive advantage in the pain management market. Future opportunities include expanding the product pipeline and exploring new therapeutic applications.

This segment is dedicated to developing treatments for CNS disorders, including post-traumatic stress disorder (PTSD) and other neurological conditions. The primary product in this segment is PES200, a novel therapeutic for the management of PTSD. Research and development activities involve investigating the underlying mechanisms of CNS disorders and identifying innovative drug targets. Technologies such as Molecular Envelope Technology (MET) are utilized to enhance drug delivery to the brain. Clinical trials are designed to assess the efficacy and safety of PES200 in reducing PTSD symptoms and improving patient quality of life. The market positioning focuses on addressing unmet medical needs in the treatment of CNS disorders, offering potential for significant growth and impact on patient care. Future opportunities include expanding the pipeline to include treatments for other neurological conditions.

This segment is focused on developing innovative anti-viral therapies to prevent or reduce the risk and intensity of viral infections, including influenza and SARS-CoV-2 (COVID-19). The lead product in this segment is MMS019, a high-density molecular masking spray designed to provide a protective barrier against viral entry. Research and development efforts are directed towards optimizing the formulation and delivery of MMS019 to maximize its effectiveness. Clinical trials are conducted to evaluate the safety and efficacy of MMS019 in preventing viral infections and reducing disease severity. The market positioning emphasizes the potential of MMS019 to provide a non-pharmacological approach to viral protection, offering a competitive advantage in the market for anti-viral products. Future opportunities include expanding the application of MMS019 to other viral infections and exploring new technologies for viral prevention.